Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202


The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, Sankaran-Walters S, Syvanen M, Wong JK, George MD, Dandekar S.

J Virol. 2011 May;85(10):4772-82. doi: 10.1128/JVI.02409-10.


Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.

Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M.

PLoS Pathog. 2012 Feb;8(2):e1002506. doi: 10.1371/journal.ppat.1002506.


Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.

AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.


Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS.

J Infect Dis. 2011 Jul 1;204(1):135-8. doi: 10.1093/infdis/jir208.


Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.

Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, Gandhi RT, Keele BF, Li JZ.

J Virol. 2015 Nov 18;90(3):1369-76. doi: 10.1128/JVI.02139-15.


Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.

Sahu GK, Paar D, Frost SD, Smith MM, Weaver S, Cloyd MW.

J Med Virol. 2009 Jan;81(1):9-15. doi: 10.1002/jmv.21366.


Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.

Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD.

PLoS Pathog. 2013 Feb;9(2):e1003174. doi: 10.1371/journal.ppat.1003174.


Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.

Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, Flamm J, Wegelin J, Prindiville T, Dandekar S.

J Virol. 2006 Aug;80(16):8236-47.


Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.

Rozera G, Abbate I, D'Offizi G, Corpolongo A, Narciso P, Vlassi C, Martini F, Calcaterra S, Capobianchi MR.

J Med Virol. 2007 Aug;79(8):1047-54.


HIV-1 proviral DNA loads (as determined by quantitative PCR) in patients subjected to structured treatment interruption after antiretroviral therapy failure.

Komninakis SV, Santos DE, Santos C, Oliveros MP, Sanabani S, Diaz RS.

J Clin Microbiol. 2012 Jun;50(6):2132-3. doi: 10.1128/JCM.00393-12.


Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue.

Talal AH, Monard S, Vesanen M, Zheng Z, Hurley A, Cao Y, Fang F, Smiley L, Johnson J, Kost R, Markowitz MH.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):1-7.


Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.

Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, Piacentini L, Vago GL, Balotta C, Moroni M, Franzetti F, Clerici M, Gori A.

Antivir Ther. 2009;14(3):321-30.


Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubó J, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR Study Team..

Antivir Ther. 2012;17(3):577-83. doi: 10.3851/IMP2025. Erratum in: Antivir Ther. 2012;17(3):597.


Seminal reservoirs during an HIV type 1 eradication trial.

Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, Pomerantz RJ.

AIDS Res Hum Retroviruses. 2005 Sep;21(9):768-75.


Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.

Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, Saksena NK.

J Clin Virol. 2005 Jul;33(3):206-16.


Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.

Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, Delbeke E.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):44-55.


HIV reservoir dynamics in the face of highly active antiretroviral therapy.

Costiniuk CT, Jenabian MA.

AIDS Patient Care STDS. 2015 Feb;29(2):55-68. doi: 10.1089/apc.2014.0173.


Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.


Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART.

Wang YM, Dyer WB, Workman C, Wang B, Peng NK, Lachireddy K, Chew CB, Sullivan J, Saksena NK.

Curr HIV Res. 2007 Mar;5(2):235-50.

Items per page

Supplemental Content

Support Center